	US 12,234,286 B2
	Anti-TIGIT antibodies and their use as therapeutics and diagnostics
Tong Zhang, Beijing (CN); Liu Xue, Beijing (CN); Qi Liu, Beijing (CN); Min Wei, Beijing (CN); and Kang Li, Beijing (CN)
Assigned to BEIGENE SWITZERLAND GMBH, Basel (CH)
Filed by BEIGENE SWITZERLAND GMBH, Basel (CH)
Filed on Nov. 24, 2021, as Appl. No. 17/534,916.
Application 17/534,916 is a division of application No. 16/958,262, granted, now 11,214,616, previously published as PCT/CN2018/125375, filed on Dec. 29, 2018.
Claims priority of application No. PCT/CN2017/120392 (WO), filed on Dec. 30, 2017.
Prior Publication US 2022/0153837 A1, May 19, 2022
Int. Cl. A61K 39/00 (2006.01); C07K 16/28 (2006.01); A61K 45/06 (2006.01)

CPC C07K 16/2803 (2013.01) [A61K 45/06 (2013.01); C07K 2317/24 (2013.01); C07K 2317/54 (2013.01); C07K 2317/55 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01)]

20 Claims

1. A method for treating a cancer or a tumor, comprising administrating to a subject in need thereof an antibody, which is capable of binding to human Tigit, or antigen binding fragment thereof comprising:

(a) a heavy chain variable region (VH) comprising heavy chain complementarity determining region (CDR)1, CDR2, and CDR3 comprising amino acid sequences of SEQ ID NOs: 3, 13, and 5, respectively; and

(b) a light chain variable region (VL) comprising light chain CDR1, CDR2, and CDR3 comprising amino acid sequences of SEQ ID NOs: 6, 7 and 8, respectively.